🎉 M&A multiples are live!
Check it out!

Entera Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Entera Bio and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

Entera Bio Overview

About Entera Bio

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.


Founded

2009

HQ

United States of America
Employees

20

Website

enterabio.com

Financials

LTM Revenue $0.2M

LTM EBITDA n/a

EV

$70.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Entera Bio Financials

Entera Bio has a last 12-month revenue of $0.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Entera Bio achieved revenue of $0.2M and an EBITDA of -$9.5M.

Entera Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Entera Bio valuation multiples based on analyst estimates

Entera Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $0.2M XXX XXX XXX
Gross Profit $33K n/a XXX XXX XXX
Gross Margin Infinity% 0% XXX XXX XXX
EBITDA -$8.8M -$9.5M XXX XXX XXX
EBITDA Margin -Infinity% -5270% XXX XXX XXX
Net Profit -$13.1M -$8.9M XXX XXX XXX
Net Margin -Infinity% -4911% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Entera Bio Stock Performance

As of April 15, 2025, Entera Bio's stock price is $2.

Entera Bio has current market cap of $79.0M, and EV of $70.6M.

See Entera Bio trading valuation data

Entera Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$70.6M $79.0M XXX XXX XXX XXX $-0.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Entera Bio Valuation Multiples

As of April 15, 2025, Entera Bio has market cap of $79.0M and EV of $70.6M.

Entera Bio's trades at 390.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Entera Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Entera Bio and 10K+ public comps

Entera Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $70.6M XXX XXX XXX
EV/Revenue 390.3x XXX XXX XXX
EV/EBITDA -7.4x XXX XXX XXX
P/E -8.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Entera Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Entera Bio Valuation Multiples

Entera Bio's NTM/LTM revenue growth is -100%

Entera Bio's revenue per employee for the last fiscal year averaged $9K, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Entera Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Entera Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Entera Bio and other 10K+ public comps

Entera Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -5270% XXX XXX XXX XXX
EBITDA Growth 8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $9K XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 2815% XXX XXX XXX XXX
R&D Expenses to Revenue 2486% XXX XXX XXX XXX
Opex to Revenue 5301% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Entera Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Entera Bio M&A and Investment Activity

Entera Bio acquired  XXX companies to date.

Last acquisition by Entera Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Entera Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Entera Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Entera Bio

When was Entera Bio founded? Entera Bio was founded in 2009.
Where is Entera Bio headquartered? Entera Bio is headquartered in United States of America.
How many employees does Entera Bio have? As of today, Entera Bio has 20 employees.
Who is the CEO of Entera Bio? Entera Bio's CEO is Ms. Miranda Jayne Toledano.
Is Entera Bio publicy listed? Yes, Entera Bio is a public company listed on NAS.
What is the stock symbol of Entera Bio? Entera Bio trades under ENTX ticker.
When did Entera Bio go public? Entera Bio went public in 2018.
Who are competitors of Entera Bio? Similar companies to Entera Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Entera Bio? Entera Bio's current market cap is $79.0M
What is the current revenue of Entera Bio? Entera Bio's last 12-month revenue is $0.2M.
What is the current EV/Revenue multiple of Entera Bio? Current revenue multiple of Entera Bio is 390.3x.
Is Entera Bio profitable? Yes, Entera Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.